You are right buildit, NGIO IPO is the top priority right now. That will give them all the funds they need without "begging" China to pay their contracted upfront payments and Bintai to somehow come up with paying their contracted invoices. GNBT can no longer rely on assistance from others. Get NGIO listed. They received their $500M+ valuation 2 months ago and Joe was quoted as saying in the 1/8/2021 PR "In addition, I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq." That is a very detailed, specific quote from Joe in the PR. However when the conf call happened, Joe started off by saying they are in a quiet period and now couldn't update any of that. So no "timing" and no update on the "last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq".

By listing NGIO at $5/share, GNBT will have a $320M+ stake in NGIO which they could sell a $50M stake to fund all operations and restart revenue streams. Joe said on the conf call, the NGIO listing is all in Dawson James' hands now. They do this for a living and have investors lined up for IPOs. Some here say that it is the NASDAQ holding things up. Not sure why since this was to be the cleanest company to by IPOd. Dawson just needs to find an investor willing to buy 10M shares at $5/share, so $50M of IPO money (less fees) to NGIO to get rid of going concerns and fund at least 1 year worth of company expenses.

Of course, all of this is my opinion and you should not make any investment decisions based on my opinion.